Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer

European Journal of Cancer

Volumn 41, Issue 4, 2005, Pages 555-563

  Jayson, Gordon C ^a   Mulatero, Clive ^a   Ranson, Malcolm ^a   Zweit, Jamal ^a,b   Jackson, Alan ^c   Broughton, Lynn ^a   Wagstaff, John ^d   Hakansson, Leif ^e   Groenewegen, Gerard ^f   Lawrance, Jeremy ^a   Tang, Meina ^g   Wauk, Linda ^g   Levitt, Dan ^g   Marreaud, Sandrine ^h   Lehmann, Frederic F ^h   Herold, Manfred ⁱ   Zwierzina, Heinz ⁱ  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c Stopford Building   (United Kingdom)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g PROTEIN DESIGN LABS INC   (United States)

^h EORTC DATA CENTER   (Belgium)

ⁱ UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Angiogenesis; Antibody; Phase I clinical trial; VEGF

Indexed keywords

MONOCLONAL ANTIBODY HUMV833; RECOMBINANT ANTIBODY; SCATTER FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; BLOOD TOXICITY; BODY WEIGHT DISORDER; CANCER PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FLUSHING; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERBILIRUBINEMIA; HYPERNATREMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; INFECTION; MALE; MELANOMA; MYALGIA; NAUSEA; NEUROTOXICITY; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECTUM HEMORRHAGE; SIDE EFFECT; SOLID TUMOR; STOMATITIS; THROMBOPLASTIN TIME; TOXICITY TESTING; VOMITING;

EID: 20044381863     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.11.021     Document Type: Article

References (27)

1. W. Risau Mechanisms of angiogenesis Nature 386 6626 1997 671 674
2. P. Carmeliet, and R.K. Jain Angiogenesis in cancer and other diseases Nature 407 6801 2000 249 257
3. D.O. Bates, T.G. Cui, and J.M. Doughty VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma Cancer Res 62 14 2002 4123 4131
4. C. Robinson, and S. Stringer The splice variants of vascular endothelial growth factor (VEGF) and their receptors J Cell Sci 114 5 2001 853 865
5. S.E. Duff, C. Li, and M. Jeziorska Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy Br J Cancer 89 3 2003 426 430
6. B.P. Eliceiri, and D.A. Cheresh The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development J Clin Invest 103 9 1999 1227 1230
7. J. Hasan, and G.C. Jayson VEGF antagonists Expert Opin Biol Ther 1 4 2001 703 718
8. J. Holash, S. Davis, and N. Papadopoulos VEGF-trap: a VEGF blocker with potent antitumor effects Proc Natl Acad Sci USA 99 17 2002 11393 11398
9. C.E. Whittles, T.M. Pocock, and S.R. Wedge ZM323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity Microcirculation 9 6 2002 513 522
10. B. Morgan, A.L. Thomas, and J. Drevs Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies J Clin Oncol 21 21 2003 3955 3964
11. A.D. Laird, J.G. Christensen, and G. Li SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice Faseb J 16 7 2002 681 690
12. D.B. Mendel, R.E. Schreck, and D.C. West The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function Clin Cancer Res 6 12 2000 4848 4858
13. S.R. Wedge, D.J. Ogilvie, and M. Dukes ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Res 62 16 2002 4645 4655
14. M.S. Gordon, K. Margolin, and M. Talpaz Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer J Clin Oncol 19 3 2001 843 850
15. K. Margolin, M.S. Gordon, and E. Holmgren Phase I B trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data J Clin Oncol 19 3 2001 851 856
16. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer N Engl J Med 350 23 2004 2335 2342
17. J.C. Yang, L. Haworth, and R.M. Sherry A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 2003 427 434
18. C.G. Willett, Y. Boucher, and E. di Tomaso Direct evidence that the VEGF specific antibody bevacizumab has antivascular effects in human rectal carcinoma Nat Med 10 2 2004 145 147
19. B.C. Kuenen, L. Rosen, and E.F. Smit Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors J Clin Oncol 20 6 2002 1657 1667
20. Johnson DH, DeVore R, Kabbinavar F. et al. Carboplatin (C) + paclitaxel (T) + RhuMab-VEGF (AVF) may prolong survival in advanced non-squamous lung cancer.Proc Am Soc Clin Oncol 2001 (abstract 1256)
21. M. Asano, A. Yukita, and H. Suzuki Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor Jpn J Cancer Res 90 1 1999 93 100
22. G.C. Jayson, J. Zweit, and A. Jackson Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies J Natl Cancer Inst 94 19 2002 1484 1493
23. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 2000 205 216
24. Langmuir VK, Cobleigh MA, Herbst RS, et al. Successful long-term therapy with bevacizumab (Avastin) in solid tumors. Proc Am Soc Clin Oncol 2002 (abstract 32)
25. Jackson A, Haroon H, Zhu XP et al. GJ Breath hold perfusion and permeability mapping of hepatic malignancies using magnetic resonance imaging and a first pass leakage profile model. NMR Biomed 2002. 15, 164-173
26. A. Jackson, G.C. Jayson, and K.L. Li Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma Br J Radiol 76 2003 153 162
27. E. Fuhrmann-Benzakein, M.N. Ma, and L. Rubbia-Brandt Elevated levels of angiogenic cytokines in the plasma of cancer patients Int J Cancer 85 1 2000 40 45